Synonyms: Braftovi® | LGX-818 | LGX818
encorafenib is an approved drug (FDA and EMA (2018))
Compound class:
Synthetic organic
Comment: Encorafenib (LGX-818) is an orally available BRAF kinase inhibitor with antineoplastic activity.
|
|
Bioactivity Comments |
Encorafenib inhibits the BRAFV600E kinase with an IC50 of 4 nM [2]. |